Spots Global Cancer Trial Database for Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Official Title: Phase II Study of Lenalidomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme.

Study ID: NCT00165477

Conditions

Glioblastoma

Gliosarcoma

Malignant Gliomas

Interventions

lenalidomide

Radiation

Study Description

Brief Summary: - The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.

Detailed Description: * Patients will receive lenalidomide orally once daily for 21 days followed by a one week rest period (this is equivalent to one cycle). * Four to seven days from the first dose of lenalidomide, the patient will start radiation therapy for approximately 6-7 weeks. * A neurologic exam and routine blood tests will be performed weekly while the patient is receiving radiation therapy. * Following the 11th week of treatment a MRI/CT scan will be performed to assess the status of the tumor. If there is no change, or there is shrinkage in the size of the tumor, the treatment will continue for another 4 week cycle. * The four week cycle will continue as long as the disease remains stable or improved and the patient does not develop intolerable side effects. A MRI/CT scan will be done every 2 cycles (8 weeks).